Related Experiment Videos
[Prognostic factors affecting survival in multiple myeloma]
J Tornóczky1, A Tóth, E Sziládi
1Megyei Kórház-Rendelöintézet Szekszárd, IV. sz. Belgyógyászati Osztály.
Orvosi Hetilap
|August 5, 1990
Summary
This study observed 70 multiple myeloma patients, finding that advanced stages and specific cell types significantly impact survival. Prognostic factors like disease stage and cell maturity are crucial for multiple myeloma patient outcomes.
Area of Science:
- Hematology
- Oncology
Context:
- Multiple myeloma is a cancer of plasma cells.
- Long-term patient observation is essential for understanding disease progression and survival.
Purpose:
- To analyze survival data and prognostic factors in a cohort of 70 multiple myeloma patients.
- To identify key indicators influencing patient outcomes in multiple myeloma.
Summary:
- The study followed 70 multiple myeloma patients for over 15 years, with 52 deceased and 18 under care.
- Median survival was 27 months for deceased patients and 50.8 months for those followed.
- Prognostic factors including Durie and Salmon stage, myeloma cell type, and paraprotein type (IgG, IgA, Bence-Jones, IgD) were analyzed.
- Stage I patients survived 60 months, Stage II 33 months, and Stage III 9 months.
- Patients with well-matured myeloma cells had a 46-month survival, while blast-cell types had 10 months.
- Concomitant severe diseases and decreased serum IgA levels in IgG myeloma patients correlated with poorer survival.
Impact:
- Identifies critical prognostic factors for multiple myeloma, aiding in risk stratification.
- Highlights the importance of considering disease stage, cell type, and comorbidities for patient management.
- Provides valuable data for future research and clinical trial design in multiple myeloma.